Lake Street Sticks to Its Buy Rating for NeuroPace (NPCE)
NeuroPace(NPCE.US) 10% Shareholder Sells US$409.43K in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 29,206 shares of common stock on May 1, 2, 3, 2024 at an average price of $14.02 for a total value of $409.43K. This transaction involves
NeuroPace(NPCE.US) 10% Shareholder Sells US$25,040.86 in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 1,781 shares of common stock on Apr 24, 2024 at an average price of $14.06 for a total value of $25,040.86. This transaction involves oth
NeuroPace(NPCE.US) 10% Shareholder Sells US$913.06K in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 64,653 shares of common stock on Apr 19, 22, 23, 2024 at an average price of $14.12 for a total value of $913.06K. This transaction invol
NeuroPace(NPCE.US) 10% Shareholder Sells US$238.23K in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 16,992 shares of common stock on Apr 16, 17, 18, 2024 at an average price of $14.02 for a total value of $238.23K. This transaction invol
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report
NeuroPace(NPCE.US) 10% Shareholder Sells US$7.03 Million in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 485K shares of common stock on Apr 11, 12, 2024 at an average price of $14.49 for a total value of $7.03 million. This transaction involv
Is NeuroPace (NASDAQ:NPCE) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
'Time to Hit Buy,' Says Wells Fargo About These 2 Stocks
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the
Former Neuropace CEO Takes the Helm at Revamp Medical
Revamp Medical Announces Appointment of Mike Favet as CEO
NETANYA, Israel, March 21, 2024 /PRNewswire/ -- Revamp Medical, Inc., a privately held clinical-stage medical technology company committed to developing solutions for Heart Failure congestion managem
NeuroPace Raised to Overweight From Equal-Weight by Wells Fargo
NeuroPace Raised to Overweight From Equal-Weight by Wells Fargo
Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16
NeuroPace (NPCE) has an average rating of buy and price targets ranging from $13 to $20, according to analysts polled by Capital IQ. Price: 14.32, Change: +0.94, Percent Change: +7.03
NeuroPace Is Maintained at Overweight by JP Morgan
NeuroPace Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $17
JP Morgan analyst Robbie Marcus maintains NeuroPace with a Overweight and raises the price target from $9 to $17.
NeuroPace Shares Target Lifted to $17 by JPMorgan
Earnings Update: Here's Why Analysts Just Lifted Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$16.00
It's been a mediocre week for NeuroPace, Inc. (NASDAQ:NPCE) shareholders, with the stock dropping 16% to US$13.98 in the week since its latest annual results. Revenue hit US$65m in line with fo
NeuroPace Full Year 2023 Earnings: EPS Beats Expectations
Neuropace, Inc.'s New Economy & Political Environment Risk – A Cause for Worry?
No Data